Fundraising Fox

Swanneck

Founded 2023 · 12 employees on LinkedIn · 1 known investors

Swan Neck Bio produces DIRINOC, a ready-to-use, quality-certified starter culture (inoculum) developed from a client's own microbial strain for use in fermentation and biomanufacturing. It applies single-use bioreactor (FlexCell) technology and an AI-assisted development program to create stable, concentrated seed cultures of yeasts, filamentous fungi, and other microbes for biomanufacturers.

Also known as Swan Neck Bio · Swanneck

Investors · 1

Company profile

researched Aug 2026

Swan Neck Bio is a fermentation company that produces DIRINOC, a ready-to-use, quality-certified starter culture (inoculum) developed from a customer's own microbial strain and delivered on demand for direct use in fermentation. The product is positioned as a substitute for in-house seed-train propagation, with the stated aim of reducing contamination risk, improving fermentation consistency, standardizing seed-train operations and shortening production timelines. The company states a shelf life claim of 95% viability at three months.

Customer strains are taken through the Organism Robustness Induction Program (ORIP), a development pathway that begins with the transfer of the client's strain and ends with an orderable, stable starter culture. ORIP comprises metabolic pathway mapping using a proprietary AI model to suggest strategies for producing a stable, storable and concentrated starter culture; wet lab trials to determine media formulation, propagation conditions, and concentration and packaging strategy; and a validation run on the FlexCell production platform, at which point quality certification and packaging logistics are set.

Swan Neck Bio describes itself as part of White Labs, a fermentation company operating since 1995, and applies White Labs' FlexCell single-use bioreactor technology — originally developed for brewing, where yeast is grown and packaged in the same vessel — to seed cultures for biomanufacturing. A third-party directory describes the company as providing fermentation solutions that help food and biotech companies of all sizes scale, commercialize and deploy microorganisms more cheaply and quickly.

Business model

The company develops a bespoke starter culture from a client's strain through the ORIP program and then supplies that culture as an orderable product, DIRINOC, on demand. Its website's calculator prices DIRINOC per batch in euros as a function of production bioreactor working volume (priced at the nearest 1,000 L step, within a 1,000–190,000 L range) and annual batch count, which drives a quantity discount capped at 70 batches per year, plus a €1,000 startup fee. Figures are described as indicative and not a binding quote, varying with seed-train setup, process, strain and production requirements.

Traction

The company cites internal production data from DIRINOC starter cultures used in selected Pichia pastoris and Saccharomyces cerevisiae fed-batch processes, where strike volume is 40% of final working volume, and references approximately 30 years of market experience with yeast starter cultures. It was ranked #483 in the 2024 edition of the Forward Fooding FoodTech 500.

▸Full profile — market position, technology, go-to-market, geography, history

Market position

The company positions DIRINOC as an outsourced alternative to in-house seed-train propagation and cites roughly 30 years of market experience with yeast starter cultures through its affiliation with White Labs. It was ranked #483 in Forward Fooding's FoodTech 500 (2024 edition), with a total score of 104.56 across business size (25.12), digital footprint (21.14) and sustainability (58.3) components.

Delivery of a quality-certified, concentrated, ready-to-use inoculum developed from the client's own strain, produced on single-use FlexCell bioreactor technology and supported by AI-assisted metabolic pathway mapping; the platform is described as microbe-agnostic, extending beyond Pichia and Saccharomyces yeasts to filamentous fungi and both wild type and GMO organisms.

Technology

Production uses the FlexCell single-use bioreactor platform, originating from White Labs, in which cells are grown and packaged in the same vessel. Strain development uses a proprietary AI model for metabolic pathway mapping to identify strategies for stable, storable, concentrated starter cultures, followed by wet trials for media formulation, propagation conditions, and concentration/packaging strategy, and a validation run for quality certification. The platform is described as organism-agnostic, covering Pichia and Saccharomyces yeasts, filamentous fungi and other microbes, wild type or GMO.

Go-to-market

Inbound lead generation via the company website, including an online starter-culture calculator that estimates per-batch DIRINOC cost, seed-train days saved and shelf life in exchange for contact details, and a form inviting prospects to describe their organism, process and production goals for an assessment of the path to a DIRINOC starter culture.

Biomanufacturers running fermentation processes, including CDMOs/CMOs, industrial producers with or without their own equipment, and early stage startups; the company's cited internal production data covers Pichia pastoris and Saccharomyces cerevisiae fed-batch processes. A third-party directory categorizes the company under food processing and biotech/synthesis, serving food and biotech companies.

Geography

Listed with a location in Copenhagen, Denmark; the company describes serving biomanufacturing applications around the world.

History

Swan Neck Bio is part of White Labs, described as a global fermentation company active since 1995 whose FlexCell technology enabled yeast to be grown and packaged in the same vessel for the brewing industry. Swan Neck Bio applies that single-use bioreactor technology to produce ready-to-use seed cultures of microbes for biomanufacturing.

Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.

Key figures

latest reported
DIRINOC shelf life (95% viability)Jan 20263 months
FoodTech 500 rankingJan 2024483 rank
FoodTech 500 total scoreJan 2024104.6
Latest funding round stageNov 2025Angel round

Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.

▸Research sources · 8

primary sources listed

8 public sources were cited for this profile; the first-party ones are listed here.

Frequently asked questions

What does Swanneck do?
Swan Neck Bio develops DIRINOC, a ready-to-use, quality-certified starter culture made from a client's own microbial strain.
Who are Swanneck's investors?
Swanneck's investors include Angular Ventures.